Clinical trials: Phenylephrine
- Condition Phenylephrine
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.
- Trial name
- NCT04795479
- Testing
- Relacorilant, Moxifloxacin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Smoking Cessation
Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between three new nicotine gum formulations and a reference nicotine gum in healthy smokers.
- Trial name
- NCT02356913
- Testing
- Nicotine gum
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin.
- Trial name
- NCT01325415
- Testing
- NKTR-118, moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market.
- Trial name
- NCT05380947
- Testing
- BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF), Rabeprazole sodium
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Moderate Pain
A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets
The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets
- Trial name
- NCT03225352
- Testing
- 500 mg acetylsalicylic acid (Aspirin, BAYE4465), 1000 mg acetylsalicylic acid (Aspirin, BAYE4465), 400 mg ibuprofen(Nurofen)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Bioavailability, Pharmacokinetics
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
Study in healthy males to assess bioavailability of 4 different fostamatinib tablets
- Trial name
- NCT01208155
- Testing
- Fostamatinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer Disease
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).
- Trial name
- NCT00979316
- Testing
- BMS-708163, Moxifloxacin
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects
The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state…
- Trial name
- NCT02273557
- Testing
- Asasantin ER (new formulation I - low), Asasantin ER (new formulation III - medium), Asasantin ER (new formulation II - high)
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Respiratory Tract Infections
To Test Bioequivalence Between Two Formulations of Paracetamol/Phenylephrine
This study is designed to assess bioequivalence between two paracetamol/ phenylephrine combination products.
- Trial name
- NCT01112462
- Testing
- Paracetamol 500 mg/Phenylephrine 5 mg tablets, Paracetamol 1000 mg/Phenylephrine 10 mg sachet
- Where
- Ireland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- McNeil AB
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.
- Trial name
- NCT01045083
- Testing
- RO4917523, escitalopram, methylphenidate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.
This study is a single-center, open-label, single-dose trial performed in a randomized, four-way, change-over design in healthy volunteers.
- Trial name
- NCT06870422
- Testing
- Esflurbiprofen Topical System
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Teikoku Seiyaku Co., Ltd.
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet coadministered with canagliflozin in healthy…
- Trial name
- NCT02851212
- Testing
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Mydriasis
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
This study evaluated pupil dilation after administration of fixed combination tropicamide-phenylephrine (TR/PH) vs. placebo. Participants attended 3 visits.
- Trial name
- MIST-2 (NCT03751098)
- Testing
- Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Eyenovia Inc.
Healthy
Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects
The purpose of this study is to assess the affect that PF-00232798 has on QT interval. A prolonged QT interval is a risk factor for arrhythmias.
- Trial name
- NCT01140425
- Testing
- PF-00232798, Moxifloxacin
- Where
- Singapore
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pharmacology
A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men
The purpose of this study is to evaluate the effect of timing of food intake on systemic abiraterone exposure observed in healthy adult Japanese and Caucasian men.
- Trial name
- NCT01575587
- Testing
- Abiraterone: Treatment A, Abiraterone: Treatment B, Abiraterone: Treatment C
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteer
A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects
This single-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled four-way crossover study will evaluate the effect of a single dose of danoprevir with low-dose ritonavir on the QC/QTc interval in…
- Trial name
- NCT01398293
- Testing
- danoprevir, moxifloxacin, ritonavir
- Where
- France
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Participants
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
- Trial name
- NCT06916143
- Testing
- LY4100511, Rabeprazole
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.
- Trial name
- NCT05630274
- Testing
- Selpercatinib, Moxifloxacin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company